Biopharmx (BPMX) Trading Down 0%
Biopharmx Corp (NYSEAMERICAN:BPMX) shares traded down 0% on Thursday . The stock traded as low as $0.18 and last traded at $0.18. 4,546,957 shares were traded during trading, a decline of 61% from the average session volume of 11,589,708 shares. The stock had previously closed at $0.18.
Separately, Maxim Group restated a “buy” rating and set a $1.50 price objective on shares of Biopharmx in a report on Friday, December 8th.
The company has a market cap of $25.50, a price-to-earnings ratio of -0.67 and a beta of 1.40.
In other news, Director Stephen Morlock bought 330,000 shares of the stock in a transaction dated Friday, November 24th. The stock was bought at an average price of $0.15 per share, for a total transaction of $49,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.